Know How Sotagliflozin Compares to Other SGLT2 Inhibitors

July 2023

New sotagliflozin (Inpefa) will try to compete with other SGLT2 inhibitors (dapagliflozin, empagliflozin, etc).

Sotagliflozin is NOT approved for managing type 2 diabetes yet...although A1c lowering seems similar to other SGLT2 inhibitors.

Instead, expect reps to tout sotagliflozin to reduce heart failure risk...especially for patients with a recent HF hospitalization.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote